证券代码：600867 证券简称：通化东宝 编号：2023-052 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 603,027,966 股，占公司目前股份总额的 30.25%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 469,489,472 股，占 其所持有公司股份总额的 77.86%，占公司目前股份总额的 23.55%。其中：东宝 集团持有公司股份 591,699,387 股，占公司目前股份总额的 29.68%，东宝集团 持有公司股份累计质押数量（本次解押及再质押后）为 469,489,472 股，占其所 持有公司股份总额的 79.35%，占公司目前股份总额的 23.55%。 2023 年 8 月 17 日,本公司接到东宝集团关于股份质押相关情况的告知函, 具体情况如下 ...

证券代码：600867 证券简称：通化东宝 公告编号：2023-034 通化东宝药业股份有限公司 关于 2022 年度暨 2023 年第一季度业绩说明会 变更会议召开信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 22 日（星期一） 14:30-16:00 会 议 召 开 地 点 ： 全 景 网 " 投 资 者 关 系 互 动 平 台 " （ 网 址 ： https://rs.p5w.net/c/600867） 会议召开方式：网络在线问答互动 （二）会议召开地点： 全 景 网 " 投 资 者 关 系 互 动 平 台 " （ 网 址 ： https://rs.p5w.net/c/600867） （三）会议召开方式：网络在线问答互动 三、参加人员 公司董事长兼总经理冷春生先生；副总经理兼董事会秘书苏璠女士；总会计 师迟军玉先生；董事、副总经理张国栋先生（负责销售）；董事、副总经理张文 海先生（负责销售）；独立董事毕焱女士将出席本次网上业绩说明会。 四、投资者参加方式 ...

Financial Performance - The net profit attributable to the parent company for 2022 was CNY 1,581,891,736.52, with the parent company achieving a net profit of CNY 1,611,418,685.58 after a 10% statutory surplus reserve allocation of CNY 161,141,868.56[4] - The total distributable profit at the end of 2022 was CNY 3,025,515,327.35, after accounting for the beginning retained earnings of CNY 2,700,547,905.49 and the payment of ordinary share dividends amounting to CNY 1,095,782,446.10[4] - The proposed cash dividend distribution is CNY 2.50 per 10 shares (including tax), totaling CNY 495,919,668.50 (including tax) based on the adjusted share capital[4] - The cash dividend accounted for 74.36% of the net profit attributable to shareholders in the consolidated financial statements for the year[5] - The company’s net profit attributable to ordinary shareholders for the year was 1,581,891,736.52 RMB, with a dividend payout ratio of 62.70%[168] Revenue and Profit Trends - The company's operating revenue for 2022 was ¥2,778,453,059.19, a decrease of 14.98% compared to ¥3,267,897,464.66 in 2021[20] - The net profit attributable to shareholders for 2022 was ¥1,581,891,736.52, an increase of 20.92% from ¥1,308,254,212.79 in 2021[20] - The net cash flow from operating activities decreased by 26.88% to ¥863,094,112.65 in 2022 from ¥1,180,365,738.97 in 2021[20] - The total profit for 2022 was CNY 1,829.52 million, an increase of 19.23% year-on-year[31] Market Position and Product Development - The company’s insulin product sales volume reached 73.76 million units in 2022, a year-on-year increase of 14.92%[34] - The market share of human insulin increased to 40.50%, surpassing Novo Nordisk, making the company the leader in the national market[34] - The company expanded its product portfolio with the approval of Aspart Insulin 30 and Aspart Insulin 50 injections, enhancing treatment options[33] - The company is focusing on expanding its research in endocrine metabolism, with ongoing projects in diabetes and gout treatments[35] Research and Development - The company has developed a comprehensive product line in diabetes treatment, including long-acting, medium-acting, and rapid-acting insulin, as well as GLP-1RA products[66] - The company is advancing its GLP-1 receptor agonist research, with Liraglutide injection expected to receive market approval by the end of 2023[44] - The company has established R&D centers in multiple cities, continuously enhancing its research capabilities and focusing on diabetes and other endocrine diseases[99] - The company reported a significant investment of RMB 4,977.59 million in the development of soluble insulin injections, which accounted for 1.79% of operating income, reflecting a 206.93% increase compared to the previous year[109] Corporate Governance and Compliance - The company has maintained stable leadership with no changes in the board of directors and senior management during the reporting period[137] - The company is committed to developing a management framework that supports long-term growth and addresses challenges related to rapid expansion[125] - The company has implemented management control over subsidiaries, ensuring compliance with relevant laws and regulations[178] - The company has not faced any penalties from securities regulatory authorities in the past three years[144] Environmental Responsibility - The company has actively invested in environmental protection measures, including upgrades to coal-fired boiler emission control systems[183] - The company has transitioned to using natural gas as the primary fuel for its boilers, eliminating the use of coal and reducing air pollution[193] - The company has published its 2022 Social Responsibility Report, available on the Shanghai Stock Exchange website[195] - The company has established an emergency response plan for environmental incidents, which was approved by experts and filed with the local environmental protection bureau in October 2022[188] Employee Management and Incentives - The company is implementing a multi-layered incentive mechanism to improve employee performance and retention, including performance assessments and stock options[52] - The company has established a training plan to enhance employee skills, including new employee orientation, on-the-job training, and external training programs[162] - The total number of employees at the parent company and major subsidiaries is 3,054, with 3,021 at the parent company and 33 at major subsidiaries[160] - The company emphasizes a reasonable salary policy based on employee qualifications, skills, and work performance, ensuring mutual benefit between labor and management[161] Strategic Initiatives - The company is actively seeking local partners in various regions to strengthen its international market presence and enhance overseas commercialization efforts[49] - The company plans to explore the potential of GLP-1RA drugs in treating obesity and NASH, with the global obesity drug market projected to reach $54 billion by 2030 and the NASH drug market expected to reach $32.2 billion[56] - The company is committed to expanding its international presence by registering insulin and GLP-1RA products in overseas markets and seeking partnerships with large foreign pharmaceutical companies[123] - The company aims to provide integrated solutions for diabetes management, including a complete insulin supply system and high-quality blood glucose monitoring systems[120]

Financial Performance - The company's operating revenue for Q1 2023 was ¥665,357,856.54, representing a decrease of 25.03% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was ¥250,436,583.32, down 69.87% year-on-year[4] - Basic earnings per share for Q1 2023 were ¥0.13, a decrease of 69.63% year-on-year[5] - The company reported a significant decline in investment income by 97.34%, primarily due to the previous year's gains from the sale of shares in Xiamen Te Bao Biological Engineering Co., Ltd.[9] - The net profit attributable to the parent company decreased by 55.78%, mainly due to price reductions in biological products following centralized procurement[9] - Total revenue for Q1 2023 was approximately ¥665.36 million, a decrease of 25% compared to ¥887.48 million in Q1 2022[18] - Net profit for Q1 2023 was approximately ¥250.67 million, a decline of 70% from ¥831.18 million in Q1 2022[19] - The total profit for Q1 2023 was approximately ¥291.34 million, a decrease of 70% compared to ¥979.84 million in Q1 2022[19] Cash Flow and Assets - The net cash flow from operating activities was ¥156,380,702.45, reflecting a decline of 55.78% compared to the previous year[4] - Cash flow from operating activities for Q1 2023 was approximately ¥156.38 million, down 56% from ¥353.63 million in Q1 2022[21] - The cash and cash equivalents at the end of the period amounted to 858,223,602.54 CNY, down from 1,039,713,134.29 CNY year-over-year[22] - The net increase in cash and cash equivalents for the quarter was 70,160,771.56 CNY, compared to 174,673,588.90 CNY in the previous period[22] - The company reported cash and cash equivalents of CNY 858,223,602.54, an increase from CNY 788,062,830.98 in the previous year, representing a growth of about 8.89%[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,998,080,337.53, an increase of 3.67% from the end of the previous year[5] - The company's current assets totaled CNY 2,228,093,885.84, up from CNY 2,056,412,954.78 in the previous year, indicating an increase of about 8.34%[14] - The total liabilities of the company were CNY 200,011,583.14, slightly down from CNY 200,740,113.58 as of December 31, 2022, showing a decrease of about 0.36%[16] - The equity attributable to shareholders reached CNY 6,792,832,969.04, an increase from CNY 6,544,263,425.28 at the end of 2022, marking a growth of approximately 3.79%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 89,451[10] - The largest shareholder, Dongbao Industrial Group Co., Ltd., held 29.68% of the shares, with 510,209,472 shares pledged[10] Research and Development - The company has maintained a strong focus on research and development, with significant investments in innovative drug formulations and technologies[15] - Research and development expenses for Q1 2023 were approximately ¥27.83 million, a slight decrease from ¥29.33 million in Q1 2022[18] Future Outlook - The company plans to expand its market presence and invest in new product development to enhance its competitive edge in the pharmaceutical industry[15] - The management expressed optimism about future growth prospects, citing ongoing projects and potential market opportunities in the pharmaceutical sector[15] Investment Activities - The net cash flow from investing activities was -86,189,926.05 CNY, compared to -137,608,286.47 CNY in the previous period[22] - The company reported a significant decrease in investment payments, totaling 58,000,000.00 CNY compared to 599,000,000.00 CNY in the previous period[22]

Financial Performance - The net profit attributable to the parent company for 2022 was CNY 1,581,891,736.52, with the parent company achieving a net profit of CNY 1,611,418,685.58 after a 10% statutory surplus reserve allocation of CNY 161,141,868.56[6]. - The total distributable profit at the end of 2022 was CNY 3,025,515,327.35, after accounting for the beginning retained earnings of CNY 2,700,547,905.49 and deducting the paid dividends of CNY 1,095,782,446.10[6]. - The proposed cash dividend distribution is CNY 2.50 per 10 shares (including tax), amounting to a total of CNY 495,919,668.50[6]. - The cash dividend for the year accounted for 74.36% of the net profit attributable to shareholders in the consolidated financial statements[7]. - The company's operating revenue for 2022 was CNY 2,778,453,059.19, a decrease of 14.98% compared to 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 1,581,891,736.52, representing a 20.92% increase from the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 840,685,707.65, down 23.90% from 2021[25]. - The cash flow from operating activities for 2022 was CNY 863,094,112.65, a decline of 26.88% year-on-year[25]. - The basic earnings per share for 2022 was CNY 0.79, an increase of 23.44% compared to 2021[26]. - The weighted average return on equity increased to 24.52% in 2022, up by 2.44 percentage points from 2021[27]. - The total assets at the end of 2022 were CNY 6,750,313,677.18, reflecting a 3.53% increase from the end of 2021[25]. - The total profit for 2022 was CNY 1,829.52 million, an increase of 19.23% year-on-year, while net profit attributable to the parent company was CNY 1,581.89 million, up 20.92% year-on-year[38]. Dividend Policy - The company plans to maintain its dividend distribution ratio even if there are changes in the total share capital before the dividend record date[9]. - The company has not proposed any stock bonus or capital reserve conversion into shares for this year[9]. - The company’s cash dividend policy is in compliance with the relevant laws and regulations, ensuring clarity in dividend standards and procedures[199]. - The company’s total share capital is 1,993,678,653 shares, with 9,999,979 shares repurchased, resulting in a base of 1,983,678,674 shares for dividend calculations[196]. - The company’s profit distribution plan for 2022 is pending approval from the annual general meeting[196]. - The company has maintained a positive profit for distribution to shareholders during the reporting period[200]. - The company has ensured that minority shareholders have ample opportunity to express their opinions and protect their rights[199]. Market Performance and Strategy - The company’s insulin product sales volume reached 73.76 million units in 2022, representing a year-on-year growth of 14.92%, with human insulin formulations experiencing nearly double-digit growth[41]. - The market share of human insulin increased to 40.50%, surpassing Novo Nordisk, while the market share of glargine insulin rose to approximately 5.90%[41]. - The company’s strategic response to the insulin procurement policy has allowed it to maintain strong sales growth despite price reductions, demonstrating effective market strategies[41]. - The company is focusing on expanding its treatment areas beyond diabetes to include gout and hyperuricemia, with ongoing research on multiple new drugs[42]. - The company is actively expanding into the GLP-1RA, DPP-4, and SGLT-2 classes of diabetes medications, with several products receiving regulatory approvals, including DPP-4 drug sitagliptin and SGLT-2 drug empagliflozin[71]. - The company has established a professional sales team and a self-operated model in the diabetes field, enhancing product coverage and market share[79]. - The company is enhancing its diabetes management platform and point-of-care testing projects to improve patient care and hospital collaboration[40]. Research and Development - The company is committed to increasing R&D investment to enhance innovation capabilities and maintain its leading position in the industry[71]. - The company’s R&D expenses for the year were CNY 146,708,531.50, a decrease of 12.07% compared to the previous year[87]. - The total R&D investment for the period was CNY 401,392,202.20, accounting for 14.45% of operating revenue[99]. - The company has established a new R&D center to enhance efficiency and integrate various departments[81]. - The company has a comprehensive product pipeline covering various insulin formulations and innovative drugs, catering to diverse patient needs in diabetes management[70]. - The company is actively developing new products, including GLP-1 receptor agonists and various insulin formulations[128]. - The company has received clinical approval for the injection of THDBH121 for type 2 diabetes in January 2023, marking a key milestone in its product pipeline[122]. Corporate Governance - The company has established a robust corporate governance structure, holding multiple shareholder and board meetings to ensure compliance and transparency[154]. - The company completed 4 periodic reports and 102 temporary announcements in the reporting period, ensuring timely and accurate information disclosure to investors[155]. - The company has maintained the independence of its operations without significant influence from controlling shareholders[156]. - The company’s management team includes individuals with extensive experience in pharmaceutical research and development, contributing to innovation[160]. - The company’s governance structure includes a compensation committee that oversees the remuneration policies for its executives[166]. - The company has been actively involved in the election of independent directors to maintain governance standards[167]. Employee Management - The total number of employees in the parent company is 3,021, with a combined total of 3,054 employees including major subsidiaries[189]. - The company has 1,258 sales personnel, representing approximately 41.2% of the total workforce[189]. - The company emphasizes a training program aimed at improving employee skills and overall efficiency, including various training methods such as internal and external training[191]. - The company has established a stock incentive plan, which includes stock options and restricted stock, to motivate employees[186]. - The company has a significant number of employees with higher education, with 1,305 individuals holding a university degree or above, accounting for approximately 42.7% of the workforce[189]. Risks and Challenges - The company faces risks from industry policy changes, particularly related to drug pricing and procurement, which could impact profitability[149]. - The company is addressing potential risks associated with environmental regulations and rising production costs due to its expanding operations[150].

证券代码：600867 证券简称：通化东宝 公告编号：2023-023 通化东宝药业股份有限公司关于 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 22 日(星期一) 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 15 日(星期一) 至 5 月 19 日(星期五)前登录上证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （thdb600867@thdb.com）进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 通化东宝药业股份有限公司（以下简称"公司"）分别于 2023 年 4 月 21 日、4 月 27 日发布公司 2022 年年度报告及 2 ...

Financial Performance - The net profit attributable to the parent company's shareholders for the first half of 2022 was CNY 1,182,565,653.56[3]. - The company's operating revenue for the first half of the year was ¥1,387,525,870.51, a decrease of 16.53% compared to the same period last year[17]. - Net profit attributable to shareholders increased by 75.49% to ¥1,182,565,653.56, driven by gains from the sale of shares in Te Bao Bio[17][19]. - The net profit after deducting non-recurring gains and losses was ¥441,299,473.10, down 32.67% year-on-year[17]. - Basic earnings per share rose to ¥0.59, reflecting a 78.79% increase compared to the previous year[18]. - The weighted average return on net assets increased by 6.00 percentage points to 17.69%[18]. - The total profit for the same period was CNY 1,383.29 million, an increase of 74.33% year-on-year[39]. - The company reported a total comprehensive income of CNY 1,184,488,919.00 for the first half of 2022, compared to CNY 700,664,943.10 in the previous year[121]. Dividend Distribution - The proposed cash dividend is CNY 2.50 per 10 shares (including tax), totaling CNY 499,544,648.00 (including tax)[3]. - The cash dividend represents 42.24% of the net profit attributable to the parent company's shareholders for the period[3]. - The company plans to maintain the distribution ratio even if there are changes in the total share capital before the dividend distribution date[3]. - The profit distribution plan has been approved by the company's board and supervisory board, ensuring no harm to the interests of shareholders, especially minority shareholders[73]. Research and Development - The company is focused on the research and development of diabetes and endocrine-related drugs, with a comprehensive product line in the diabetes treatment field[24]. - The company has a comprehensive product pipeline in diabetes treatment, including long-acting, medium-acting, and rapid-acting insulin, as well as innovative drugs[32]. - The company is actively expanding its research and development efforts in the endocrine metabolism field, including gout and hyperuricemia[32]. - The company continues to focus on innovative R&D, expanding treatment areas with three new diabetes drugs and two new gout/hyperuricemia drugs in development[42]. - The company has developed a robust R&D pipeline, with two out of five global innovative drugs entering Phase I clinical trials during the reporting period[35]. Market Strategy and Challenges - The impact of national centralized procurement on insulin prices has significantly affected the company's revenue, necessitating adjustments in pricing strategies[19]. - The implementation of national centralized procurement for insulin starting in May 2022 led to a decrease in revenue due to price adjustments and one-time write-offs[29]. - The company aims to enhance its market share by increasing investments in retail channels and private hospitals outside the centralized procurement framework[29]. - The company is facing risks from industry policy changes, particularly due to increased regulatory scrutiny and price reductions from centralized procurement[65]. Environmental Compliance - The company achieved compliance with the emission standards for both wastewater and exhaust gas, with key pollutants meeting regulatory limits[78]. - The company invested over 110 million yuan in environmental protection from 2018 to the first half of 2022, focusing on wastewater treatment upgrades and waste gas treatment facilities[87]. - The company has established an online monitoring system for wastewater discharge, ensuring continuous compliance with environmental standards[78]. - The company is committed to reducing carbon emissions and enhancing resource recycling, with a focus on low-carbon operations[88]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 112,821[104]. - The largest shareholder, Dongbao Industrial Group Co., Ltd., holds 591,699,387 shares, accounting for 29.44% of total shares[105]. - The company completed the repurchase of 23,999,946 shares at a price of 8.29 yuan per share, reducing its registered capital accordingly[101]. - The company has implemented a stock option and restricted stock incentive plan to align the interests of shareholders, the company, and core team members[74]. Financial Position - Total assets at the end of the reporting period were ¥6,912,464,695.87, up 6.02% from the end of the previous year[17]. - The company's cash and cash equivalents at the end of the reporting period amount to RMB 1,078,768,444.66, an increase from RMB 865,039,545.39 at the beginning of the period[111]. - The total liabilities decreased to CNY 176,201,221.90 from CNY 299,874,064.97, a decline of approximately 41%[114]. - The company's retained earnings increased to CNY 3,283,236,981.45 from CNY 2,700,547,905.49, reflecting a growth of around 21.5%[114].

Financial Performance - The company's operating revenue for Q1 2022 was ¥887,477,252.42, representing a year-on-year increase of 7.85%[4] - The net profit attributable to shareholders was ¥831,206,165.81, showing a significant increase of 146.90% compared to the same period last year[4] - The basic earnings per share for the period was ¥0.41, reflecting a growth of 141.18% year-on-year[4] - Total operating revenue for Q1 2022 was ¥887,477,252.42, an increase of 7.97% compared to ¥822,877,442.06 in Q1 2021[19] - Net profit for Q1 2022 reached ¥831,177,167.14, a significant increase of 147.00% compared to ¥336,685,623.32 in Q1 2021[20] - Earnings per share for Q1 2022 was ¥0.41, compared to ¥0.17 in Q1 2021, marking a growth of 141.18%[21] - The total comprehensive income attributable to shareholders of the parent company for Q1 2022 was ¥831,206,165.81, compared to ¥336,658,081.42 in Q1 2021[21] Assets and Liabilities - Total assets reached ¥7,303,544,733.34, marking a 12.02% increase from the previous year[5] - The total assets as of Q1 2022 amounted to ¥7,303,544,733.34, an increase from ¥6,520,101,831.69 in the previous year[19] - The total liabilities as of Q1 2022 were ¥301,997,696.34, slightly up from ¥299,874,064.97 in the previous year[19] - Total current liabilities were reported at RMB 271,011,360.23, compared to RMB 268,552,310.27 in the previous year, showing a slight increase[16] - Non-current assets totaled RMB 4,397,685,201.79, a marginal increase from RMB 4,357,640,813.80 year-over-year[16] Cash Flow - The net cash flow from operating activities was ¥353,628,438.63, which decreased by 4.76% compared to the same period last year[4] - Cash inflow from operating activities for Q1 2022 was CNY 889,818,138.33, an increase from CNY 822,296,308.62 in Q1 2021, representing a growth of approximately 8.2%[22] - Total cash inflow from operating activities was CNY 353,628,438.63, down from CNY 371,302,361.29 in the same period last year, showing a decrease of about 4.9%[22] - The net increase in cash and cash equivalents for Q1 2022 was CNY 174,673,588.90, down from CNY 202,911,569.62 in Q1 2021, reflecting a decrease of about 13.9%[23] - The company reported a net cash outflow from financing activities of CNY -41,346,559.10 in Q1 2022, slightly improved from CNY -44,565,001.00 in Q1 2021[23] Investments - Investment income surged by 4240.60%, primarily due to the transfer of shares in a subsidiary[8] - The company reported an investment income of ¥530,762,988.19 in Q1 2022, a substantial increase from ¥12,227,878.38 in Q1 2021[19] - The company completed the transfer of 20,350,000 shares of Xiamen Te Bao Biological Engineering Co., Ltd. at a price of RMB 22.608 per share, totaling RMB 460,072,800[13] - A second transfer of 20,500,000 shares of Te Bao Biological was executed at RMB 20.16 per share, amounting to RMB 413,280,000, with the transfer still in process as of the report date[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 114,221, with the largest shareholder holding 29.44% of the shares[9] - The total equity attributable to shareholders of the parent company increased to ¥6,996,226,972.18 from ¥6,214,878,703.23, representing a growth of 12.55%[19] Research and Development - Research and development expenses for Q1 2022 were ¥29,327,431.35, down from ¥37,980,616.37 in Q1 2021, indicating a decrease of 22.83%[19] Inventory and Receivables - The company reported inventory of RMB 521,039,722.68, down from RMB 537,917,743.37, indicating a decrease of approximately 3.15%[15] - Accounts receivable increased to RMB 599,172,165.02 from RMB 559,472,847.32, reflecting a growth of approximately 7.07%[15] Cash and Cash Equivalents - The company's cash and cash equivalents amounted to RMB 1,039,713,134.29, up from RMB 865,039,545.39 in the previous year, indicating a year-over-year increase of about 20.19%[15] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 1,039,713,134.29, up from CNY 594,943,313.72 at the end of Q1 2021, reflecting an increase of approximately 74.7%[23]

Financial Performance - The net profit attributable to the parent company for 2021 was CNY 1,378,563,889.56, with a total distributable profit of CNY 2,700,547,905.49 after accounting for dividends paid[2]. - The cash dividend for the year accounted for 45.85% of the net profit attributable to shareholders in the consolidated financial statements[2]. - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) to all shareholders, totaling CNY 599,876,577.60[2]. - The company reported a net profit of CNY 1,308,254,212.79 for the year, with a significant portion of profits retained for future distribution[2]. - The company's operating revenue for 2021 was CNY 3,267,897,464.66, representing a year-on-year increase of 12.99% compared to CNY 2,892,169,238.81 in 2020[15]. - Net profit attributable to shareholders for 2021 reached CNY 1,308,254,212.79, a significant increase of 40.69% from CNY 929,916,045.06 in 2020[15]. - The total profit reached CNY 1.5344528 billion, reflecting a year-on-year growth of 38.47%[23]. - The net profit attributable to shareholders was CNY 1.3082542 billion, up 40.69% compared to the previous year[23]. - The company’s total assets at the end of 2021 were CNY 6,520,101,831.69, reflecting a growth of 12.35% from CNY 5,803,260,212.00 at the end of 2020[15]. - Basic earnings per share for 2021 were CNY 0.64, an increase of 39.13% compared to CNY 0.46 in 2020[17]. - The weighted average return on equity for 2021 was 22.08%, an increase of 4.36 percentage points from 17.72% in 2020[17]. Research and Development - The company established an innovation drug R&D center in Hangzhou and introduced three new diabetes treatment drugs in 2021[28]. - The company is expanding its treatment portfolio to include new drugs for gout and hyperuricemia, with clinical trials approved for two new drugs[29]. - The company has achieved full coverage in the research and development of insulin analogs, GLP-1 receptor agonists, and high clinical value oral hypoglycemic drugs, accelerating the progress of its R&D pipeline[32]. - The company completed the production of three batches of insulin analog GLP-1RA compound preparations in 2021 and is conducting stability and non-clinical studies[30]. - The company has made significant progress in the clinical trials of rapid-acting insulin and GLP-1 receptor agonists, with liraglutide injection entering the Pre-NDA stage[39]. - The company is actively enhancing its diabetes management platform and POCT project to improve patient care and communication[25]. - The company is focusing on innovative drug development, with significant investments in multi-target diabetes drugs and small molecule drugs[105]. - The company has ongoing clinical trials for multiple diabetes-related drugs, including THDBH110 and THDBH120[100]. - The company aims to enhance its core competitiveness through increased R&D spending in response to market changes[104]. Market and Sales - The company is positioned as a leader in the insulin market, continuously increasing its market share since breaking the foreign monopoly on insulin in China[50]. - The sales revenue of insulin raw materials and injections reached CNY 2.419 billion, a year-on-year increase of 6.83%[26]. - The sales revenue of insulin analogs raw materials and injections surged to CNY 401 million, marking a 204.79% year-on-year growth[26]. - The company’s insulin product sales volume increased by over 200% year-on-year, with successful bidding in over 3,800 hospitals[25]. - The company is actively expanding its product pipeline in the diabetes treatment sector, including long-acting, medium-acting, and rapid-acting insulin products, as well as GLP-1RA formulations[53]. - The company is focusing on expanding its market presence in the diabetes and hyperuricemia treatment sectors, which are expected to grow significantly in the coming years[89]. Corporate Governance - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, complying with relevant regulations[122]. - The board of directors consists of 9 members, including 3 independent directors, and held 13 board meetings during the reporting period[123]. - The supervisory board is composed of 3 members, including 1 employee representative, and held 6 meetings during the reporting period[123]. - The company has established and optimized internal control systems to enhance risk prevention capabilities and operational standards[123]. - The company maintains a commitment to fair treatment of all investors and actively engages in investor relations through various channels[123]. Environmental Responsibility - The company reported a total wastewater discharge of 364,853 m³ for the year 2021, with COD concentration at 24.9875 mg/L, well below the permitted limit of 80 mg/L[171]. - The company generated a total of 45.313 tons of hazardous waste in 2021, all of which was legally disposed of by a licensed hazardous waste management unit[171]. - The company has implemented a comprehensive emergency plan for environmental incidents, which was revised in 2023[179]. - The company has established a stable operation of pollution prevention facilities, achieving over 95% removal efficiency for sulfur dioxide[176]. - The company has invested over 100 million yuan in environmental protection initiatives from 2018 to mid-2022, focusing on wastewater treatment upgrades and waste gas treatment facilities[185]. Employee and Talent Management - The company has a diverse workforce with 1,188 sales personnel and 516 technical staff[154]. - The company emphasizes employee training programs to enhance overall quality and work efficiency[157]. - The company has strengthened its human resources system, introducing key talents such as the Vice President of R&D and Chief Human Resources Officer to enhance overall team capability[45]. - The company is focused on expanding its talent pool and improving employee training to support its rapid growth and enhance overall employee quality[118]. Risk Management - The company faces risks related to industry policy changes, particularly with the implementation of centralized drug procurement, which may impact pricing and profitability[119]. - The company acknowledges potential challenges from rising production costs and stricter environmental regulations, which could affect profitability[119]. - The company is actively addressing R&D risks by focusing on developing diabetes treatment products, which are expected to drive new growth opportunities[119].